Repligen (NASDAQ:RGEN) Given New $200.00 Price Target at JPMorgan Chase & Co.

Repligen (NASDAQ:RGEN) had its price objective lifted by equities researchers at JPMorgan Chase & Co. from $190.00 to $200.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 24.14% from the company’s previous close.

Other analysts have also recently issued reports about the stock. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Canaccord Genuity Group upped their price objective on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday. HC Wainwright reissued a “buy” rating and issued a $180.00 target price on shares of Repligen in a research report on Friday. Finally, Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $183.36.

Repligen Price Performance

Shares of RGEN traded down $1.56 during mid-day trading on Friday, reaching $161.11. 51,787 shares of the company’s stock were exchanged, compared to its average volume of 586,809. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $113.50 and a 52-week high of $203.13. The company has a market cap of $9.03 billion, a price-to-earnings ratio of -435.42, a PEG ratio of 4.23 and a beta of 0.99. The company has a 50-day simple moving average of $155.17 and a two-hundred day simple moving average of $148.81.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. On average, sell-side analysts predict that Repligen will post 1.54 EPS for the current fiscal year.

Institutional Trading of Repligen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Champlain Investment Partners LLC raised its holdings in shares of Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after acquiring an additional 850,345 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Repligen by 11.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock worth $1,027,165,000 after buying an additional 743,815 shares during the period. Point72 Asset Management L.P. raised its position in Repligen by 183.1% during the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock valued at $132,227,000 after buying an additional 594,189 shares during the period. Groupama Asset Managment lifted its stake in Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock worth $58,142,000 after acquiring an additional 400,680 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new position in Repligen during the 4th quarter valued at about $53,428,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.